Dark

ANGO
AngioDynamics, Inc.
stock NASDAQ

At Close

Aug 14, 2026 3:59:50 PM EDT

15.87USD+1.341%(+0.21)330,037

13.47Bid 15.92Ask 2.45Spread

Pre-market

Aug 13, 2026 8:42:30 AM EDT

16.21USD+3.512%(+0.55)0

After-hours

Aug 12, 2026 4:05:30 PM EDT

13.96USD-11.308%(-1.78)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 7, 2022

01:06PM EST AngioDynamics Earnings Perspective: Return On Capital Employed Benzinga

Jan 6, 2022

07:17AM EST AngioDynamics Q2 Net Loss $8.4 Mln Or $0.21/shr Vs. Net Loss Of $4.3 Mln Or $0.11/shr Prior Year RTTNews

07:16AM EST AngioDynamics Q2 Net Sales $78.3 Mln, Increase Of 7.6% From Last Year RTTNews

07:10AM EST AngioDynamics Cuts FY22 EPS Guidance From $0.00-$0.05 To $(0.02)-$0.02 Vs. $0.02 Est. Benzinga

07:09AM EST AngioDynamics Q2 EPS $(0.02) Down From $0.01 YoY, Sales $78.28M Beat $77.88M Estimate Benzinga

07:00AM EST AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance Business Wire

04:14AM EST Earnings Scheduled For January 6, 2022 Benzinga

Jan 3, 2022

04:01PM EST AngioDynamics to Present at the Needham Virtual Growth Conference Business Wire

Dec 15, 2021

04:01PM EST AngioDynamics to Report Fiscal 2022 Second Quarter Financial Results on January 6, 2022 Business Wire

Oct 15, 2021

10:15AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 15, 2021 Benzinga

07:29AM EDT 10 Biggest Price Target Changes For Friday Benzinga

06:22AM EDT Canaccord Genuity Upgrades AngioDynamics to Buy, Raises Price Target to $37 Benzinga

Oct 1, 2021

06:56AM EDT After an upbeat fiscal first quarter, AngioDynamics Inc. (ANGO) appears confident in its future as it continues to execute its strategic plan of transformation into a high-growth Med Tech company. RTTNews

Sep 30, 2021

02:51PM EDT Mid-Afternoon Market Update: Gold Rises 2%; Bed Bath & Beyond Shares Slide Benzinga

12:11PM EDT Mid-Day Market Update: Dow Drops Over 300 Points; Virgin Galactic Shares Jump Benzinga

10:10AM EDT Mid-Morning Market Update: Markets Mixed; CarMax Profit Misses Views Benzinga

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

07:26AM EDT While reporting financial results for the first quarter on Thursday, medical devices company AngioDynamics, Inc. (ANGO) maintained its adjusted earnings guidance for the full year 2022, while raising annual net sales outlook. RTTNews

07:05AM EDT AngioDynamics Q1 Net Loss $7.0 Mln Or $0.18/Shr Vs Loss $4.3 Mln Or $0.11/shr Last Year RTTNews

07:04AM EDT AngioDynamics Sees FY22 EPS $0.00-$0.05 Vs. $0.01 Est., Raises Sales Guidance From $305M-$310M To $310M-$315M Vs. $307.82M Est. Benzinga

07:02AM EDT AngioDynamics Q1 EPS $(0.02) Beats $(0.04) Estimate, Sales $77.00M Beat $71.31M Estimate Benzinga

07:00AM EDT AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance Business Wire

03:40AM EDT Earnings Scheduled For September 30, 2021 Benzinga

Sep 15, 2021

04:01PM EDT AngioDynamics to Report Fiscal 2022 First Quarter Financial Results on September 30, 2021 Business Wire

Aug 20, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021 Benzinga

08:36AM EDT Oppenheimer Initiates Coverage On AngioDynamics with Perform Rating Benzinga

Jul 29, 2021

04:02PM EDT AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference Business Wire

Jul 14, 2021

10:29AM EDT UPDATE: Raymond James on AngioDynamics Buy Reiteration: Firm Highlights Accelerating Revenue Growth Over Next 3 Years 'Culminating In Double-Digit Growth In F24'; Sees AlphaVac As Co.'s Biggest Ever Product Opportunity Launching In The Fall Benzinga

10:28AM EDT Raymond James Reiterates Strong Buy Rating On AngioDynamics With $32 Price Target Benzinga

10:23AM EDT Canaccord Genuity Maintains Hold on AngioDynamics, Raises Price Target to $28 Benzinga

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 13, 2021

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

08:03AM EDT AngioDynamics, Inc. (ANGO) on Tuesday reported net loss of $19.5 million, or $0.51 per share, in the fourth quarter, narrower than $157.0 million, or $4.13 per share in the same quarter a year ago. RTTNews

07:53AM EDT AngioDynamics Breaks-Even In FY21, Issues Mixed Forecasts For FY22 Benzinga

07:39AM EDT While reporting financial results for the fourth quarter on Tuesday, medical devices company AngioDynamics, Inc. (ANGO) initiated its adjusted earnings and net sales guidance for the full year 2022. RTTNews

07:13AM EDT AngioDynamics Q4 EPS $0.00 vs $(0.06) In Same Qtr. Last Year, Sales $76.84M Beat $72.67M Estimate Benzinga

07:08AM EDT AngioDynamics Q4 Net Loss $19.5 Mln Or $0.51 Per Share Vs Loss $157.0 Mln Or $4.13/Shr A Year Ago RTTNews

07:07AM EDT AngioDynamics Sees FY22 EPS $0.00-$0.05 Vs. $0.07 Est., Sales $305M-$310M Vs. $297.9M Est. Benzinga

07:06AM EDT AngioDynamics Q4 Sales $76.84M Beat $72.67M Estimate Benzinga

07:01AM EDT AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results Business Wire

04:54AM EDT Earnings Scheduled For July 13, 2021 Benzinga

Jul 9, 2021

07:54AM EDT Raymond James Maintains Strong Buy on AngioDynamics, Raises Price Target to $32 Benzinga

Jul 8, 2021

06:30PM EDT AngioDynamics Announces Details for Investor & Technology Day on July 13, 2021 Business Wire

Jun 25, 2021

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

Jun 24, 2021

04:01PM EDT AngioDynamics to Report Fiscal 2021 Fourth Quarter and Full-Year Financial Results and Host Investor & Technology Day on July 13, 2021 Business Wire

08:12AM EDT The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO Benzinga

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

Jun 22, 2021

08:12AM EDT The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal Benzinga

Jun 10, 2021

08:13AM EDT The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal Benzinga

Jun 9, 2021

09:14AM EDT The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US Benzinga

Jun 8, 2021

07:13AM EDT AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System Benzinga

07:10AM EDT AngioDynamics Receives 510(k) Clearance From FDA For AlphaVac Mechanical Thrombectomy System RTTNews

07:00AM EDT AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System Business Wire

Jun 1, 2021

04:01PM EDT AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (AVITA Medical), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. GlobeNewswire Inc

May 17, 2021

04:01PM EDT AngioDynamics to Present at the UBS Virtual Global Healthcare Conference Business Wire

Apr 12, 2021

06:36AM EDT AngioDynamics, Inc. (ANGO) said it submitted a 510(k) application to the FDA for the AlphaVac System, a multi-purpose mechanical aspiration thrombectomy device for the treatment of undesirable intravascular material in the venous system and peripheral vasculature. The company expects the release of the AlphaVac System in the second half of 2021, subject to FDA clearance. RTTNews

06:03AM EDT AngioDynamics Submits 510(k) Application To FDA For AlphaVac Mechanical Thrombectomy System RTTNews

Apr 7, 2021

07:58AM EDT The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award Benzinga

Apr 5, 2021

04:01PM EDT AngioDynamics to Present at the Needham Virtual Healthcare Conference Business Wire

Apr 1, 2021

07:46AM EDT The Daily Biotech Pulse: Pfizer-BioNTech Preps For BLA Filing, Sonoma Surges, BioXcel Readout, Ortho Clinical Lands Contract Benzinga

Mar 31, 2021

09:30AM EDT Canaccord Genuity Maintains Hold on AngioDynamics, Raises Price Target to $24 Benzinga

Mar 30, 2021

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

07:24AM EDT AngioDynamics Sees FY21 Adj. EPS $0.04-$0.06 vs $0.01 Est., Sales $285M-$288M vs $283.49M Est. Benzinga

07:23AM EDT AngioDynamics Q3 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $71.18M Beat $68.95M Estimate Benzinga

07:18AM EDT While reporting financial results for the third quarter on Tuesday, medical devices company AngioDynamics, Inc. (ANGO) raised its adjusted earnings and net sales guidance for the full year 2021. RTTNews

07:17AM EDT Recap: AngioDynamics Q3 Earnings Benzinga

07:05AM EDT AngioDynamics Q3 Net Loss $3.5 Mln Or $0.09 Per Share Vs Loss Of $5.7 Mln Or $0.15 Per Share A Year Ago RTTNews

07:00AM EDT AngioDynamics Reports Fiscal 2021 Third Quarter Financial Results and Updates Guidance Business Wire

04:04AM EDT Earnings Scheduled For March 30, 2021 Benzinga

Mar 29, 2021

10:08AM EDT A Preview Of AngioDynamics's Earnings Benzinga

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 19, 2021

07:46AM EDT The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs Benzinga

Mar 18, 2021

08:16AM EDT The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq Benzinga

Mar 16, 2021

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

Mar 15, 2021

04:01PM EDT AngioDynamics to Participate in a Virtual Fireside Chat at the KeyBanc Life Sciences & MedTech Investor Forum Business Wire

Mar 12, 2021

07:36AM EST The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs Benzinga

Mar 10, 2021

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

Mar 9, 2021

04:01PM EST AngioDynamics to Participate in a Virtual Fireside Chat at the Oppenheimer Healthcare Conference Business Wire

08:00AM EST AngioDynamics to Report Fiscal 2021 Third Quarter Financial Results on March 30, 2021 Business Wire

Mar 1, 2021

04:01PM EST AngioDynamics to Present at the Barclays Virtual Global Healthcare Conference Business Wire

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Feb 1, 2021

08:00AM EST AngioDynamics Appoints Richard C. Rosenzweig Senior Vice President, General Counsel and Secretary, Promotes Juan Carlos Serna to Senior Vice President, Scientific & Clinical Affairs Business Wire

Jan 21, 2021

11:32AM EST Insider Sells AngioDynamics's Stock Benzinga

Jan 8, 2021

11:10AM EST Raymond James Maintains Strong Buy on AngioDynamics, Raises Price Target to $24 Benzinga

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 7, 2021

10:32AM EST Shares of medical devices company AngioDynamics, Inc. (ANGO) are rising more than 10% Thursday morning on better-than-expected second-quarter results. RTTNews

07:20AM EST AngioDynamics Q2 Net Loss Of $4.3 Mln Or $0.11/Shr Vs Loss Of $2.7 Mln Or $0.07/Shr A Year Ago RTTNews

07:17AM EST AngioDynamics: Q2 Earnings Insights Benzinga

07:06AM EST AngioDynamics Reaffirms FY21 Adj. EPS Guidance Of $0.00-$0.0.5 vs $0.02 Est., Sales $278M-$284M vs $281.66M Est. Benzinga

07:05AM EST AngioDynamics Q2 Adj. EPS $0.01 Beats $(0.02) Estimate, Sales $72.80M Beat $67.35M Estimate Benzinga

07:00AM EST AngioDynamics Reports Fiscal 2021 Second Quarter Financial Results Business Wire

04:10AM EST Earnings Scheduled For January 7, 2021 Benzinga

Jan 6, 2021

10:14AM EST AngioDynamics Earnings Preview Benzinga

Jan 4, 2021

04:01PM EST AngioDynamics to Present at the J.P. Morgan Virtual Healthcare Conference Business Wire

Dec 29, 2020

04:01PM EST AngioDynamics to Present at the Needham Virtual Growth Conference Business Wire

Dec 9, 2020

04:01PM EST AngioDynamics to Report Fiscal 2021 Second Quarter Financial Results on January 7, 2021 Business Wire

Nov 25, 2020

09:52AM EST Benzinga's Top Upgrades, Downgrades For November 25, 2020 Benzinga

07:11AM EST Raymond James Upgrades AngioDynamics to Strong Buy, Announces $18 Price Target Benzinga

Nov 12, 2020

09:09AM EST AngioDynamics Announces Presentation Of Positive Safety, Efficacy Results From RAPID Outcomes Database Benzinga

Sep 29, 2020

01:28PM EDT This Week's Key Earnings Reports Benzinga

07:36AM EDT While reporting financial results for the first quarter of fiscal 2021 on Tuesday, medical devices company AngioDynamics, Inc. (ANGO) provided adjusted earnings and net sales guidance for the full year 2021. RTTNews

07:28AM EDT AngioDynamics Sees FY21 EPS $0.00-$0.05 Vs. $(0.10) Est., Sales $278M-$284M Vs. $274.48M Benzinga

07:15AM EDT Recap: AngioDynamics Q1 Earnings Benzinga

07:11AM EDT AngioDynamics Q1 Loss/Shr $0.11 Vs Loss $0.03 Last Year RTTNews

07:10AM EDT AngioDynamics Q1 EPS $0.02 Beats $(0.07) Estimate, Sales $70.22M Beat $65.10M Estimate Benzinga

07:00AM EDT AngioDynamics Reports Fiscal 2021 First Quarter Financial Results Business Wire

03:40AM EDT Earnings Scheduled For September 29, 2020 Benzinga

Sep 28, 2020

10:07AM EDT Earnings Outlook For AngioDynamics Benzinga

Sep 21, 2020

08:22AM EDT AngioDynamics Announces Commercial Launch Of Auryon Atherectonmy System In U.S. To Treat PAD, CLI, ISR Benzinga

08:00AM EDT AngioDynamics Announces Commercial Launch of Auryon Atherectomy System in United States Business Wire

Sep 17, 2020

04:01PM EDT AngioDynamics to Report Fiscal 2021 First Quarter Financial Results on September 29, 2020 Business Wire

Aug 17, 2020

09:33AM EDT AngioDynamics Announces First Patient Enrolled In PATHFINDER I RTTNews

08:03AM EDT AngioDynamics Announces First Patient Enrolled in PATHFINDER I Registry Examining Long-Term Effectiveness and Safety of Auryon Atherectomy System Benzinga

Aug 3, 2020

04:01PM EDT AngioDynamics to Participate in a Virtual Fireside Chat at the Canaccord Genuity Growth Conference Business Wire

Jul 17, 2020

05:08AM EDT 64 Biggest Movers From Yesterday Benzinga

Jul 16, 2020

07:25AM EDT AngioDynamics: Q4 Earnings Insights Benzinga

07:09AM EDT AngioDynamics Q4 Net Loss $156.07 Mln Vs. Net Profit $58.9 Mln Last Year RTTNews

07:00AM EDT AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results Business Wire

04:10AM EDT Earnings Scheduled For July 16, 2020 Benzinga

document.getElementById("Y4SpYh").onerror = function(){this.style.display='none';}; .dark-mode .VnxdNn{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .VnxdNn{ color: #333333; background-color: white; border: 2px solid #333333; }ANGOAngioDynamics, Inc.stock NASDAQ

ANGO
AngioDynamics, Inc.
stock NASDAQ